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Poly-L-lactic acid (PLA; Sculptra; Dermik Laboratories, Berwyn,
PA, USA) was introduced in 2004 for the treatment of facial lipoa-
trophy associated with human immunodeﬁciency virus. Later, it
gained popularity as a cosmetic volumizer for soft-tissue enhance-
ment in the general population.1 Overall, PLA injections are associ-
ated with low complication rates. Self-limited, short-term
complications include bruising and edema. Long-term complica-
tions such as clinically visible papules and subcutaneous nodules
at the injection site have also been reported.1–7 Herein, we present
a case of multiple subcutaneous granulomas formation, which was
conﬁrmed by histopathological analysis, in an immunocompetent
patient who received PLA injections for soft-tissue cosmetic
enhancement.Figure 1 (A) Multiple ﬁrm, skin-colored papules and subcutaneous nodules on t
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http://dx.doi.org/10.1016/j.dsi.2013.05.004A 62-year-old healthy woman presented to our clinic with a
complaint of multiple ﬁrm skin-colored papules and subcutaneous
nodules on the bilateral cheeks, chin, and temporal areas for 3–4
months (Figure 1). She mentioned a history of PLA (Sculptra) injec-
tion (three doses of unknown volume and dilution) during the past
year. Results of a skin biopsy revealed granulomatous dermatitis
consisting of epithelioid histiocytes, numerous multinucleated
and osteoclast-like giant cells. Many of these giant cells also had
fusiform clefts in the cytoplasm or stellate-shaped inclusion bodies
(Figure 2). The intracytoplasmic fusiform clefts were ﬁlled with
whitish birefringence crystalloid structures. The patient was
treated with intralesional triamcinolone acetonide (3 mg/mL;
0.06–0.08 mL for each lesion, three treatment sessions; treatment
duration: 2 weeks apart). After treatment, the subcutaneous nod-
ules softened and gradually shrank.he bilateral cheeks and chin. (B) The subcutaneous nodules are highlighted.
n. Published by Elsevier Taiwan LLC. All rights reserved.
Figure 2 (A) The lower-power view (2) reveals well-circumscribed oval- and S-shaped nodules. (B) The high-power view (10) reveals numerous multinucleated and osteoclast-
like giant cells, with many of them having fusiform clefts in the cytoplasm.
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silicon, and hyaluronic acid. However, the rates of PLA-induced
granulomas in the literature vary from 0.1% (reported by Vleggaar)6
to 44% (reported in the VEGA study).7 The discrepancy in the
quoted rates of foreign-body granuloma formation after PLA injec-
tion may be attributed to differences in the injection techniques
and the PLA concentrations used. Higher dilution volumes (5:1–
7:1) are associated with lower rates.1
Although the precise mechanism of PLA-induced granulomas is
uncertain, there are some proposed theories including excess PLA
deposition, an unequal distribution of PLA particles, formed local
clustering due to the lack of a massage at the injection site, clus-
tering of the large PLA particles, and different responses of various
injection sites. A previous report suggests that the incidence of
granuloma formation is greater at the periorbital skin.4 Preparation
of PLA 24 hours prior to the injection to allow even distribution of
the particles and adequate dilution volumes are recommended to
decrease this side effect.
Treatment options for subcutaneous nodules are intralesional
steroids, systemic steroids, systemic antibiotics, intense pulsed
light, 5-ﬂuorouracil, hydroxychloroquine, allopurinol, and surgical
removal.1–5 High doses of intralesional steroids (40–80 mg/mL)
may be necessary for clinical resolution in some cases.4
In summary, we report a case of nodule formation after injection
of PLA. Doctors should be aware of the risks, and caution is neces-
sary when using them. Adequate preparation, dilution, and mas-
sage at the injection site are essential to minimize the risk of side
effects. In addition, proﬁcient injection skills and sufﬁcient under-
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